Overview
Management
Scientific Team
Press Releases
Career Opportunities
CSIR lab in second licensing deal with US pharma company.
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression.
Symmetrix Pharmaceuticals Announces the Appointment of Ronald J. Shebuski, Ph.D. as Chief Scientific Officer
Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Best Viewed at 1024x768, IE 7.0
© Nostrum Pharmaceuticals LLC. 2008
